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Introduction
Each year, 5%–15% of the world’s population will suffer from an influenza infection, with up to 5 million cases 
of severe disease and 500,000 deaths (1). Influenza viruses have the ability to mutate and hence escape immune 
defense mechanisms, necessitating annual vaccine updates. These vaccines include the tetravalent inactivated 
influenza vaccine (TIV) (2), which is given intramuscularly, and the live attenuated influenza vaccine (LAIV) (3), 
which is administered intranasally. The route of vaccination can trigger distinct immune mechanisms and path-
ways of protection. For example, TIV is given as an intramuscular injection and induces neutralizing antibodies 
against strain-specific glycoproteins HA and neuraminidase (NA) (4). By comparison, LAIV is administered 
intranasally as a cold-adapted vaccine that replicates only in the nasopharynx and mimics natural infection (5). 
Nasal replication leads to recognition of its pathogen-associated molecular patterns by host pattern recognition 
receptors, which initiates a cascade of cellular immune responses (6). In mice, LAIV vaccination increases the 
frequency of CD4+ and CD8+ T cells in the lung and cytokine production upon influenza restimulation com-
pared with the inactivated virus or no vaccine administration (7–10). Moreover, LAIV seeds the murine lung 
with both CD4+ tissue-resident memory (TRM) and virus-specific CD8+ T cells. TRM T cells have been shown 
to provide long-term cross-strain protection against influenza (7). In humans, the immune responses elicited by 
LAIV have been found to provide broader clinical protection in children compared with the inactivated influ-
enza vaccines (11). However, the detailed immunological mechanisms of this remain incompletely understood.
Influenza vaccines are reformulated annually to represent circulating strains; however, genomic changes 
over time (antigenic drift) reduce effectiveness (12). Estimates from WHO suggest that influenza vaccines’ 
Influenza virus infections affect millions of people annually, and current available vaccines provide 
varying rates of protection. However, the way in which the nasal microbiota, particularly established 
pneumococcal colonization, shape the response to influenza vaccination is not yet fully understood. 
In this study, we inoculated healthy adults with live Streptococcus pneumoniae and vaccinated them 
3 days later with either tetravalent-inactivated influenza vaccine (TIV) or live attenuated influenza 
vaccine (LAIV). Vaccine-induced immune responses were assessed in nose, blood, and lung. Nasal 
pneumococcal colonization had no impact upon TIV-induced antibody responses to influenza, which 
manifested in all compartments. However, experimentally induced pneumococcal colonization 
dampened LAIV-mediated mucosal antibody responses, primarily IgA in the nose and IgG in the lung. 
Pulmonary influenza-specific cellular responses were more apparent in the LAIV group compared 
with either the TIV or an unvaccinated group. These results indicate that TIV and LAIV elicit 
differential immunity to adults and that LAIV immunogenicity is diminished by the nasal presence of 
S. pneumoniae. Therefore, nasopharyngeal pneumococcal colonization may affect LAIV efficacy.
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effectiveness rarely exceeds 60% and has fallen below 30% in some years (13, 14). Poor effectiveness of  
LAIV among youth ages 2–17 in 2014 and 2015 led to the CDC recommending its temporary exclusion 
from the US national childhood influenza immunization program during the subsequent 2 seasons (15). 
From 2018, however, no such recommendations have been made. Many underlying causes for this variation 
have been suggested, including poor matching with circulating strains (12, 16); differential ability of  some 
LAIV types to induce immunity, in particular against H1N1 strains (15); and the microbial community com-
position at times of  LAIV administration (17).
Despite several reports about the microbiota and their impact on vaccination responses (18–21), includ-
ing responses to influenza vaccine (20, 22), it remains unclear how the microbiome affects LAIV immu-
nogenicity. In murine models, a prior exposure to Streptococcus pneumoniae influenza virus potentially com-
promised long-term antiviral antibody-mediated immunity (23). Colonization of  the nasopharynx with 
pneumococcus is very common during childhood, with a point prevalence of  50% of  infants in resource-
rich settings and up to 90% in low- and middle-income countries (24). A significant interaction between 
S. pneumoniae colonization and influenza vaccination could profoundly impact the utility of  vaccination, 
especially among the poorest groups of  the world.
We used an experimental human pneumococcal challenge (EHPC) model (25) to experimentally colo-
nize adults with pneumococcus, who 3 days later received either LAIV (nasal) or TIV (intramuscular). We 
showed that in humans, LAIV elicited immune responses primarily at mucosal sites of  infection — the nose 
and lung. Interestingly, experimentally induced pneumococcal colonization affected LAIV immunogenici-
ty, dampening the LAIV-mediated nasal and lung immune responses.
Results
We conducted a double-blind randomized controlled clinical trial (26) in which healthy adults (18–48 years 
of  age) were vaccinated with either TIV (n = 90) or LAIV (n = 80) 3 days after intranasal challenge with live 
S. pneumoniae (Figure 1A). To assess and compare the immune responses elicited by influenza vaccination, 
we analyzed a series of  samples in a subset of  40 TIV and 80 LAIV vaccinated subjects. Mucosal samples, 
including nasal wash, nasal scrapes (epithelial and immune cells), nasal lining fluid, and bronchoalveolar 
lavage (BAL), as well as serum samples, were collected from the 2 experimental groups and stratified accord-
ing to vaccination and pneumococcal carriage status: (a) TIV vaccinated non–S. pneumoniae colonized 
(TIV/S. pneumoniae–, n = 21), (b) TIV vaccinated S. pneumoniae–colonized (TIV/S. pneumoniae+, n = 19), 
(c) LAIV vaccinated non–S. pneumoniae colonized (LAIV/S. pneumoniae–, n = 37), and (d) LAIV vaccinated 
S. pneumoniae-colonized (LAIV/S. pneumoniae+, n = 43). For the assessment of  lung immune responses, we 
included a nonvaccinated cohort as control (n = 20, 10 S. pneumoniae– and 10 S. pneumoniae+, respectively), 
since we were only able to sample the human lung after challenge/vaccination and not at baseline.
S. pneumoniae colonization prevents an acute nasal proinflammatory response upon LAIV administration. Vac-
cine-induced inflammatory responses in the nasal mucosa were assessed by measuring levels of  30 cyto-
kines in the nasal fluid at baseline, at day 1 (2 days after S. pneumoniae challenge but 1 day before vacci-
nation), and at 3, 6, and 24 days after vaccination. LAIV administration induced a mild proinflammatory 
response, which resembled TIV based on similarity analysis (Figure 1B). In particular, only IFN-γ–induc-
ible protein 10 (IP-10) and TNF-α were significantly increased (P < 0.05 by Wilcoxon’s test with Benjami-
ni-Hochberg adjustment for multiple testing correction) at 3 days after LAIV. At day 6, TNF-α remained 
at increased levels compared with prechallenge baseline (day 8 time point), and levels of  4 more cytokines 
(IL-1b, IL-12, IL-15, and IL-2R) had a transient induction at this time point (Figure 1C). No other cytokine 
was significantly induced in either the LAIV or TIV group at any time point.
To investigate whether colonization of  the nasopharynx with S. pneumoniae prior to transient LAIV 
infection would alter the LAIV-mediated immunogenicity, we stratified the groups according to volunteers’ 
colonization status and assessed the cytokine profile in the 4 experimental groups. LAIV induced a transient 
but robust proinflammatory response only in the absence of  nasal pneumococcal colonization (Figure 1D). 
In particular, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, IFN-γ, IFN-α, IP-10, and TNF-α 
were significantly increased from prechallenge baseline at 3 days after LAIV in the noncolonized group 
(Figure 1E). At 6 days after LAIV, 21 out of  30 measured cytokines were significantly increased in this group 
(Figure 1E). No other cytokine was significantly induced in any of  the 4 groups at any time point.
LAIV increases the frequency of  influenza-specific TNF-α– and IFN-γ–producing CD4+ and TRM CD4+ T cells in 
the lung. Data from animal models suggest that LAIV, but not TIV, induces protective cellular responses in the 
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lung (27, 28). To assess influenza vaccination-induced cellular responses in the human lung, BAL cells were 
stimulated with influenza antigens. T cell subsets (CD4+, CD8+, and TCR-γδ+) were immunophenotyped, 
and cytokine production was measured by intracellular cytokine staining in order to determine the frequency 
of  IFN-γ–, IL-17A–, and TNF-α–producing influenza-specific T cells (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.141088DS1). Frequencies of  
total CD4+, CD8+, and TCR-γδ+ T cells were not affected by vaccination status (Supplemental Figure 2). Fur-
thermore, we investigated the presence of  TRM T cell responses to influenza, using the extracellular markers 
CD69, CD103, and CD49a. Because more than one-third of  CD4+CD69+ cells, commonly defined as TRM 
(29), did not express the additional resident memory markers CD103 and CD49a, we defined TRM only as 
CD69+ (Supplemental Figure 3). In contrast, nearly all CD8+CD69+ cells also expressed CD103 and CD49a.
CD4+ TNF-α production upon influenza stimulation was observed in both TIV and LAIV recipients, 
regardless of  colonization status, but not in unvaccinated individuals (Figure 2, A and B). However, levels 
of  influenza-specific TNF-α were significantly increased in the LAIV/S. pneumoniae– group compared with 
the unvaccinated group (median 2.6-fold increase, P = 0.015; Figure 2B).
Following stimulation with influenza antigens, CD4+ TRM T cells produced TNF-α in all vaccinated 
groups but not in the unvaccinated group (Figure 2C). The induction of  TNF-α–producing CD4+ TRM T 
cells following stimulation did not significantly differ between TIV and LAIV, but it was more pronounced 
in the LAIV group, in both the S. pneumoniae– and S. pneumoniae+ groups compared with the unvaccinated 
group (7.7-FC, P = 0.004; and 6.5-FC, P = 0.024 unvaccinated, respectively, Figure 2D).
We also assessed IFN-γ production by total CD4+ and TRM CD4+ T cells residing in the human lung. 
IFN-γ production by total CD4+ T cells was observed in all groups upon stimulation, including the unvac-
cinated group (Figure 2E). The levels of  IFN-γ–producing CD4+ T cells were not different when comparing 
vaccinated and unvaccinated groups. The induction of  IFN-γ–producing CD4+ TRM T cells, however, was 
greater in the LAIV vaccinated group (Figure 2F). In contrast to total CD4+ T cells, stimulation of  TRM T 
cells of  unvaccinated individuals did not elicit an IFN-γ response (Figure 2G). Pneumococcal colonization 
status did not affect the levels of  either influenza-specific IFN-γ–producing CD4+ or TRM IFN-γ–produc-
ing CD4+ T cells (Figure 2, F–H).
Furthermore, the proportion of IL-17A–producing CD4+ T or CD4+ TRM T cells was not affected by 
vaccination with either TIV or LAIV (Supplemental Figure 4, A and B). The frequency of regulatory CD4+ T 
cells was also measured in the lung, with such cells showing increased levels in BAL samples of LAIV/S. pneu-
moniae– compared with unvaccinated individuals (mean 1.5-fold increase) (P = 0.039; Supplemental Figure 5).
LAIV increases the frequency of  influenza-specific TNF-α–producing CD8+ and TRM CD8+ T cells in the lungs. In 
vitro restimulation with influenza induced increased production of TNF-α by CD8+ T cells in the LAIV but 
not the TIV or unvaccinated group (Figure 3). When volunteers were stratified based on colonization status, 
LAIV/S. pneumoniae– had a median 2.3-fold increase of TNF-α–producing CD8+ T cells after stimulation com-
pared with the nonstimulated condition (P = 0.03). LAIV/S. pneumoniae+ group had a similar induction on 
this type of cellular response (median 1.9-fold increase, P = 0.007; Figure 3A). Similarly, TNF-α production by 
TRM CD8+ cells was observed only in the LAIV vaccinated group, increased by median 3.1-FC (P = 0.006) 
and 2.1-FC (P = 0.004) in the LAIV/S. pneumoniae– and LAIV/S. pneumoniae+ groups, respectively (Figure 3B).
Figure 1. Pneumococcal colonization prevents an acute nasal LAIV-induced proinflammatory response. (A) Healthy 
adults (n = 170) 18–48 years of age were recruited and participated in a randomized, controlled clinical trial. Subjects 
were screened 8 days prevaccination (baseline), followed by challenge with live Streptococcus pneumoniae (Spn) 3 days 
before vaccination against influenza (D-3). Then, they received either LAIV or TIV at day 0 (D0). Serum samples were 
collected at baseline (D-8) and D24. Nasal washes were collected from all volunteers at D-8, D-1, D3, D6, and D24, plus 
at D11 and D18 for the colonized. Nasal fluid and cells were collected at D-8, D-1, D3, and D6, plus at D24 for nasal fluid 
only. BAL sample was collected 26–46 days after vaccination. (B–E) Levels of 30 cytokines were measured in nasal 
fluid at baseline, 1 day before vaccination (D-1), and 3, 6, and 24 days after vaccination for LAIV/Spn– (LAIV vaccinated/
noncolonized, n = 15), LAIV/Spn+ (LAIV vaccinated/colonized, n = 15), TIV/Spn– (TIV vaccinated/noncolonized, n = 16) 
and TIV/Spn+ (TIV vaccinated/colonized, n = 14). (B and D) Samples were clustered based on fold change (FC) levels to 
baseline using t-distributed stochastic neighbor embedding for LAIV (blue) or TIV (orange). R and P values shown for 
significant time points based on analysis of similarity (anosim), including (FCs) for all cytokines. (C) Heatmap showing 
median log2FC to baseline levels at each time point after LAIV or TIV administration, irrespective of colonization status. 
Upregulation (red) and downregulation (blue) in cytokines’ levels from baseline. (E) Heatmap showing median log2FC 
to baseline levels at each time point for the 4 experimental groups, based on stratification by vaccine and colonization 
status. Statistical comparisons were applied against the baseline sample for each time point in every group inde-
pendently. **P < 0.01, *P < 0.05, Wilcoxon’s paired test with Benjamini-Hochberg correction for multiple testing.
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IFN-γ responses by lung CD8+ T cells after stimulation were confined in the LAIV group. Although 
both LAIV/S. pneumoniae– and LAIV/S. pneumoniae+ groups had the same levels of  induction (1.5-fold 
increase) in the proportion of  IFN-γ–producing CD8+ T cells after stimulation (Figure 3C), this effect was 
statistically significant only in the LAIV/S. pneumoniae+ group due to the lower variance within the group 
(Figure 3C). TIV and control groups had overall no increase in the proportion of  IFN-γ–producing CD8+ 
T cells after stimulation with influenza antigens. In addition, IFN-γ production by lung TRM CD8+ T cells 
was not significantly altered after stimulation in any of  the groups (Figure 3D).
Stimulation did not elicit production of  IL-17A–producing CD8+ T cells, except for IL-17A production 
by TRM CD8+ T cells in the S. pneumoniae–colonized group (2.6-fold increase, P = 0.008; Supplemental 
Figure 4, C and D).
LAIV increases frequency of  influenza-specific IFN-γ–producing TCR-γδ+ T cells in the lungs of  noncolonized indi-
viduals. TCR-γδ cells, a subset of  specialized innate-like T cells that can exert effector functions immediately 
upon activation, play an important role in pulmonary infection (30, 31). Therefore, we assessed whether 
TCR-γδ responses to influenza antigens were induced following vaccination. Although no significant increase 
in TNF-α–producing TCR-γδ+ was observed in any of  the groups (Figure 4A), the proportion of  IFN-γ–pro-
ducing TCR-γδ+ was significantly greater in the LAIV/group (median 2.9-fold increase upon stimulation 
compared with the unstimulated condition, P = 0.002, Figure 4B). None of  the other vaccinated or unvacci-
nated groups showed a significant induction of  IFN-γ production. Similar to the other T cell subsets, IL-17A–
producing TCR-γδ+ cells did not significantly increase after stimulation with influenza antigens (Figure 4C).
S. pneumoniae colonization impairs nasal IgA induction following LAIV but does not alter responses to TIV. 
In addition to cellular responses, we sought to assess humoral responses elicited by TIV and LAIV vacci-
nation both systemically and at the mucosal sites (nasal and lung). In serum samples, IgG levels against 
influenza antigens were measured at baseline (prior to bacterial challenge and influenza immunization) 
and at day 24 after vaccination. TIV induced a 5.9-fold increase (P < 0.0001) of  influenza-specific IgG, 
whereas LAIV intranasal administration did not confer increase of  sera IgG levels (Figure 5A). Prior 
colonization of  the nasopharynx with S. pneumoniae did not alter influenza-specific IgG levels induced in 
response to either vaccine (Figure 5B).
To assess antibody responses at the nasal mucosa, we measured influenza-specific IgA and IgG levels 
in nasal wash samples at baseline and 24 days following influenza immunization and described the kinetics 
of  influenza-specific IgM at baseline, D3, D6, D11, and D24 in both vaccine groups. TIV induced a median 
2.2- and a 5.2-fold increase in influenza virus-specific IgA and IgG levels, respectively, 24 days after vacci-
nation (Figure 5, C–F). LAIV also elicited an IgA and IgG antibody response, though both (IgA median 
1.3-fold increase and IgG median 1.4-fold increase) were lower compared with those induced by TIV (Fig-
ure 5, C–F). In addition, TIV induced an earlier and stronger IgM response in nasal mucosa compared with 
LAIV. The median levels of  influenza-specific IgM titers in nasal lavage were 1.71, 2.74, and 1.94 times 
higher compared with baseline levels at D6, D11, and D24, respectively, in the TIV group, whereas in the 
LAIV group they differed statistically significantly from baseline only at day 24 after vaccine administration 
(median 1.22-fold increase from baseline, Supplemental Figure 6A).
LAIV-mediated immunogenicity at the nasal mucosa was also dependent on S. pneumoniae coloniza-
tion, as observed for the lung cellular responses. Experimentally induced colonization of  the nasopharynx 
with S. pneumoniae affected IgA titers, but neither IgG nor IgM, in the LAIV group (Figure 5, E and F, and 
Supplemental Figure 6C). At day 24 after vaccination, the LAIV/S. pneumoniae– group had significantly 
greater levels of  IgA against influenza circulating in the nasal lumen, compared with the LAIV/S. pneumoni-
ae+ counterparts (LAIV/S. pneumoniae– median = 1.69, IQR: 0.98–2.65 vs. LAIV/S. pneumoniae+ median = 
Figure 2. LAIV increases frequency of influenza-specific TNF-α– and IFN-γ–producing CD4+ and TRM CD4+ T cells in the lung. Frequencies of cytokine- 
producing CD4+ and TRM CD4+ T cells were measured in human BAL samples by intracellular staining flow cytometry analysis with and without (mock) in 
vitro influenza antigen stimulation. Volunteers were divided by vaccine and colonization status in TIV/Spn– (n = 6), TIV/Spn+ (n = 8), LAIV/Spn– (n = 10), LAIV/
Spn+ (n = 9), and unvaccinated (n = 8, 3 Spn– and 5 Spn+) groups. (A) Production of TNF-α by total CD4+ T cells in each group (paired unstimulated [mock] and 
stimulated condition [flu]). (B) Influenza-specific production of TNF-α by total CD4+ T cells (difference between influenza-stimulated and unstimulated) in 
each group. (C) Production of TNF-α by CD4+CD69+ T cells in each group. (D) Production of influenza-specific TNF-α by CD4+CD69+ T cells in each group. (E) 
Production of IFN- γ by total CD4+ T cells in each group. (F) Production of influenza-specific IFN-γ by CD4+ T cells in each group. (G) Production of IFN-γ by 
CD4+CD69+ T cells and (H) influenza-specific IFN-γ by CD4+CD69+ T cells in each group. Each individual dot represents a single volunteer, and the conditions 
from 1 individual are connected. Medians with IQR are depicted for influenza-specific responses (B, D, F, and H). *P < 0.05, **P < 0.01 by Wilcoxon’s test for 
comparisons within the same group and by Mann-Whitney U test for between-group comparisons.
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1.24, IQR: 0.66–1.81) (P = 0.02; Figure 5E). S. pneumoniae colonization did not alter humoral responses 
to influenza in the TIV group for any antibody isotype (Figure 5, E and F, and Supplemental Figure 6B).
IgG but not IgA is induced by influenza vaccines in the lung, with LAIV-mediated responses being impaired by 
pneumococcal colonization. Humoral responses in the lung following TIV or LAIV vaccination were assessed 
in BAL samples collected between 26 and 46 days after influenza vaccination (Figure 6). Owing to the 
single time point sampling of  the lung, 20 unvaccinated subjects (10 S. pneumoniae–colonized and 10 non-
colonized) were used as a control group.
IgA against influenza levels in the lung did not differ between the TIV, LAIV, and control groups 
(Figure 6A). In terms of  IgG levels, TIV induced a high IgG response (median 5.8-fold increase compared 
with control) (P < 0.0001), whereas LAIV conferred a modest IgG induction (median 1.6-FC compared 
with control) (P = 0.028; Figure 6B). TIV-elicited influenza-specific IgG levels were 3.7 times greater than 
LAIV-induced responses in the pulmonary mucosa (Figure 6B). Despite the late time point after vaccina-
tion, IgM against influenza was detectable in the lung, and higher titers were measured in the TIV (3.3-fold 
increase compared with control) (P = 0.0003) than in the LAIV vaccinated subjects (1.81-fold increase 
compared with control) (P = 0.022; Supplemental Figure 6D).
Figure 3. LAIV increases frequency of influenza-specific TNF-α–producing CD8+ and TRM CD8+ T cells in the lungs. Frequencies of cytokine-producing 
CD8+ T cells were measured in human BAL samples by intracellular staining flow cytometry analysis following stimulation with influenza antigens or 
nonstimulation (mock) in each group. Volunteers were divided by vaccine and colonization status in TIV/Spn– (n = 6), TIV/Spn+ (n = 8), LAIV/Spn– (n = 10), 
LAIV/Spn+ (n = 9), and unvaccinated (n = 8, 3 Spn– and 5 Spn+) groups. Production of TNF-α by (A) total CD8+ T cells and (B) TRM CD8+ T cells in each group 
(paired unstimulated [mock] and stimulated condition [flu]). Production of IFN-γ production by (C) total CD8+ T cells and (D) TRM CD8+ T cells in each 
group. Each individual dot represents a single volunteer, and the conditions per individual are connected. *P < 0.05, **P < 0.01 by Wilcoxon’s test.
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IgA levels were not significantly increased in the lung by vaccination and therefore not affected by S. 
pneumoniae colonization (Figure 6C). Similar to IgA, IgM responses in the lung did not differ between S. 
pneumoniae–colonized and noncolonized subjects (Supplemental Figure 6E). However, S. pneumoniae colo-
nization affected IgG titers in the LAIV vaccinated group but not in the TIV group. IgG against influenza 
was higher in the LAIV/S. pneumoniae– group compared with the control group (1.73-fold increase, P = 
0.006), whereas the LAIV/S. pneumoniae+ group did not differ from the control (Figure 6D).
TLR priming by S. pneumoniae and increased type I IFN gene expression profile soon after nasal colonization 
establishment. To identify molecular signatures associated with reduced LAIV-mediated immunogenicity 
and impaired inflammatory responses owing to established pneumococcal nasopharyngeal colonization, 
we performed host RNA-Seq on nasal cells at baseline, day 1 (before vaccination), and at 3 and 6 days after 
vaccination. Two days after the bacterial challenge but prior to influenza vaccination, the LAIV/S. pneu-
moniae+ group showed enrichment in genes related to TLR signaling, including TLR2, TLR4, and TLR9 
(Figure 7). As expected, gene enrichment in TLR was not observed in the LAIV/S. pneumoniae– group at 
the same time point after inoculation. Additionally, the LAIV/S. pneumoniae+ group exhibited enrichment 
in IFN-α/β, IFN-γ genes and RIG-I/MDA5–mediated induction of  IFN-α/β pathways (Figure 7). The 
upregulation of  these pathways suggests that pneumococcal colonized volunteers had increased antiviral 
responses the day before the LAIV administration, a molecular profile that is likely to interfere with the 
influenza virus replication cycle in the nasopharynx.
To further investigate this observation, influenza RNA was quantified in unconcentrated nasal washes 
collected at 3 days after vaccination in the LAIV group. Only one-fourth of  the LAIV vaccinated group had 
detectable levels of  influenza viral RNA in the nose 3 days after vaccination, with no statistically significant 
differences in the levels of  influenza viral RNA (Supplemental Figure 7A) or in the percentage of  shedders 
Figure 4. LAIV increases frequency of IFN-γ–producing influenza-specific 
TCR-γδ+ in the lungs of noncolonized individuals. Frequency of cytokine- 
producing TCR-γδ+ T cells was measured in human BAL samples by intra-
cellular staining flow cytometry analysis after in vitro stimulation with 
influenza antigens or nonstimulation (mock). Volunteers were divided by 
vaccine and colonization status in TIV/Spn– (n = 6), TIV/Spn+ (n = 8), LAIV/
Spn– (n = 10), LAIV/Spn+ (n = 9), and unvaccinated (n = 8, 3 Spn– and 5 Spn+) 
groups. Production of (A) TNF-α, (B) IFN-γ, and (C) IL-17A by lung TCR-γδ T 
cells. Individual dot represents a single volunteer, and the conditions per 
individual are connected. **P < 0.01 by Wilcoxon’s test.
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Figure 5. LAIV vaccination increases levels of antibody against influenza in serum and nasal wash, with impaired nasal production caused by S. pneumoniae 
colonization. (A) IgG titers to influenza, measured by ELISA, in serum of LAIV (n = 36) and TIV (n = 36) vaccinated subjects at baseline (8 days prevaccination) and 
D24 (24 days after vaccination). (B) FC (D24/baseline) of paired IgG titers to influenza in serum following TIV or LAIV vaccination. TIV/Spn– (n = 20), TIV/Spn+ (n = 
16), LAIV/Spn– (n = 18), and LAIV/Spn+ (n = 18). (C) IgA and (D) IgG titers against influenza measured by ELISA in nasal wash of TIV (n = 40) and LAIV (n = 80) vacci-
nated subjects at baseline (8 days before vaccination) and D24 (24 days after vaccination). (E) FC (D24/baseline) of paired IgA and (F) IgG titers against influenza in 
nasal wash following vaccination with TIV/Spn– (n = 21), TIV/Spn+ (n = 19), LAIV/Spn– (n = 37), and LAIV/Spn+ (n = 43). Medians with IQR are shown. *P < 0.05, ***P 
< 0.001, ****P < 0.0001 by Wilcoxon’s test for comparisons within the same group and by Mann-Whitney U test for comparisons between groups.
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(Ct < 40) between the S. pneumoniae colonized (23.1%, 9/39) and noncolonized (27.5%, 11/40; Supple-
mental Table 1). As expected, levels of  influenza-specific IgA, following LAIV vaccination, were greater 
(2.5-FC) in the nasal mucosa of  volunteers with detectable viral influenza replication (Supplemental Figure 
7B). In contrast, raised influenza-specific IgG levels following vaccination did not differ between shedders 
and nonshedders (Supplemental Figure 7C).
Discussion
We investigated the cellular and humoral immune responses elicited by TIV and LAIV, focusing on respiratory 
mucosa, and assessed whether colonization of the nasopharynx with S. pneumoniae influences vaccine immu-
nogenicity. In agreement with previous studies (3), TIV vaccination induced high systemic and mucosal anti-
body responses, whereas LAIV elicited both mucosal (mainly IgA) influenza virus-specific antibodies and cell- 
mediated immune responses. Interestingly, experimentally induced pneumococcal colonization of the naso-
pharynx impaired host immunity to LAIV but did not alter TIV-induced responses. Antecedent pneumococcal 
colonization was also associated with weakened acute nasal proinflammatory responses after LAIV vaccination.
In the lungs, LAIV-induced cellular responses were heightened and markedly increased from those 
induced by TIV. LAIV nasal administration led to increased levels of  TNF-α– and IFN-γ–producing CD4+ 
Figure 6. IgG but not IgA is induced by influenza vaccines in the lung, with LAIV responses being reduced during S. pneumoniae colonization. (A and 
B) IgA and IgG titers against influenza for TIV (n = 20), LAIV (n = 19) vaccinated subjects and unvaccinated (n = 20) was measured by ELISA in BAL fluid. (C 
and D) IgA and IgG titers grouped based on vaccination and colonization status, as TIV/Spn– (n = 9), TIV/Spn+ (n = 11), LAIV/Spn– (n = 11), LAIV/Spn+ (n = 8), 
and unvaccinated (n = 20). Medians with IQR are shown. *P < 0.05, **P < 0.01, ****P < 0.0001 by Wilcoxon’s test for comparisons within the same group 
and by Mann-Whitney test U for comparisons between groups.
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T cells, including TRM T cells, as well as TNF-α–producing CD8+ T cells, upon in vitro stimulation. Inter-
estingly, we observed that influenza-specific CD4+ T cell lung responses were more pronounced in individ-
uals not colonized with S. pneumoniae at the time of  vaccination, suggesting increased immunogenicity of  
LAIV in the absence of  pneumococcal colonization. Similarly, there was a higher proportion of  IFN-γ–
producing TCR-γδ+ T cells in the noncolonized LAIV recipients. Moreover, LAIV was associated with 
increased frequencies of  lung Tregs but only in the absence of  nasal S. pneumoniae colonization.
Humoral responses were highly induced by TIV, whereas LAIV conferred an overall modest antibody 
induction. Systemically, TIV elicited influenza virus-specific IgG responses, which were not observed in the 
LAIV vaccinated arm. In the nose, TIV conferred predominantly IgG induction, whereas LAIV was mainly 
associated with high levels of IgA. Colonization of the nasopharynx with S. pneumoniae at the time of LAIV 
administration impaired the induction of mucosal IgA to influenza in the nose and IgG in the lung. The modu-
latory effect of S. pneumoniae on adaptive immune responses to influenza virus has been previously reported in a 
murine coinfection model, highlighting the importance of current pathogen exposure, which can critically affect 
the generation of protective antiviral antibodies and subsequently reduce influenza vaccination efficacy (23).
The protection provided by LAIV relies on a transient viral replication in the nasopharynx to induce suf-
ficient antibody levels against influenza, which we observed with increased IgA induction in shedders com-
pared with nonshedders. LAIV in adults, unlike children, does not confer superior protection compared with 
TIV (32). An explanation consistent with the hypothesis is that lifelong accumulation of  influenza immunity 
through natural exposure and previous vaccinations can prevent the nasal replication of  the attenuated virus 
and shorten the viral replication cycle (33). Here, 25.3% of  young adults vaccinated with LAIV shed atten-
uated influenza virus (either influenza A or B), in contrast to the much higher shedding rates observed in 
2- to 5-year-old children in other studies (34). Taking into consideration virus neutralization by preexisting 
Figure 7. TLR priming by S. pneumoniae and increased type I IFN gene expression profile soon after nasal colonization. Selected pathways after gene 
set enrichment analysis for LAIV/Spn– (n = 11) and LAIV/Spn+ (n = 9) groups at D-1, D3, and D6 in relation to LAIV administration applied on log2FCs (base-
line/pre-Spn inoculation-normalized values). Normalized enrichment score (NES) is presented in gradient color. Red shades indicate pathways overrepre-
sented, whereas blue shades depict the underrepresented pathways at each time point in relation to baseline (prior pneumococcal inoculation). *P < 0.05 
by Wilcoxon’s paired test corrected by multiple-comparison testing (Benjamini-Hochberg).
1 2
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(4):e141088  https://doi.org/10.1172/jci.insight.141088
antibodies against influenza due to lifetime exposure or a shortened virus replication cycle (33), increased 
influenza shedding has to be detected in the LAIV cohort in the first 2 days after the vaccine administration. 
Consequently, LAIV may elicit less potent responses in adults compared with children; thus, any extrapo-
lation from findings in adults to children, the target population for this vaccine, must be done with caution.
Children display high rates of  S. pneumoniae colonization (35, 36). Our finding that concurrent S. pneumo-
niae colonization could inhibit LAIV-induced immune responses is another variable that should be taken into 
account when evaluating LAIV efficacy. This phenomenon could explain the lack of  LAIV efficacy reported 
in Senegal (37), as S. pneumoniae colonization rates are higher in low-income countries (38). The impaired 
LAIV-induced immunity during established S. pneumoniae colonization was associated with a lack of  a proin-
flammatory response in the nasal mucosa following LAIV vaccination. An explanation for this is that S. 
pneumoniae colonization affects local immune and epithelial cell responses upon LAIV vaccination, which 
could diminish immune cell infiltration and antigen-presenting cell activation, impacting the downstream 
memory responses (39, 40). For instance, lack or reduced production of  IFNs by activated nasal cells after 
vaccination may affect innate immune responses to LAIV, by impairing NK and macrophage activation in the 
nasal mucosa and potentially DC migration and differentiation. Such an impaired innate immune response 
would also translate to reduced antigen presentation and subsequently affect the adaptive immune responses.
It is also possible that S. pneumoniae colonization interferes with the viral replication cycle (41, 42), 
through stimulation of  TLR. A number of  studies have reported the broad contribution of  TLR2 to the 
antiviral IFN response by indirectly governing the production of  IFNs induced by other TLRs, as well as 
downstream of  the cytosolic Rig-I–like receptors (43, 44). In an infant mouse influenza A–S. pneumoniae 
coinfection model, mice deficient for TLR2 showed decreased expression of  IFN-α and higher viral titers 
than WT animals, with this great viral burden correlating with heightened inflammation (45). In our study, 
S. pneumoniae–colonized volunteers upregulated genes involved in TLR2, RIG-I/MDA5-mediated induc-
tion of  IFN-α/β, and IFN-α/β pathways before exposure to LAIV and exhibited impaired inflammatory 
responses after vaccination. A strong induction of  TLR and IFN pathways by S. pneumoniae colonization 
may result in quick viral sensing and resolution of  viral infection. Despite these observations, any alteration 
of  viral replication cycle mediated by S. pneumoniae colonization was limited by the late time point of  viral 
quantification at 3 days after LAIV administration. An alternative hypothesis of  the curtailed viral shed-
ding in the LAIV/S. pneumoniae+ group would be the inhibitory effect of  pneumococcal neuraminidases, 
particularly NanA, on influenza virus attachment to the epithelium, as shown in an infant mouse model of  
the S. pneumoniae–influenza A virus coinfection model (46). In light of  these observations, it would also be 
interesting to investigate to what extent symptoms and inflammation caused by WT influenza viruses are 
altered by concurrent S. pneumoniae+ colonization in humans.
Ideally, an effective and broadly protective influenza vaccine should induce both humoral and cellular 
immunity. Whereas antibody responses to influenza show some degree of strain cross-reactivity (47, 48), they 
are insufficient to provide heterosubtypic, cross-strain influenza protection (49, 50). Recent data from longitu-
dinal cohort studies of naturally acquired infection have highlighted the potential of T cells as key players in 
mediating heterosubtypic immunity in humans (51, 52). We observed that even in the absence of vaccination, 
healthy adults showed CD4+ T cell responses to influenza stimulation, which likely reflects their lifelong expo-
sure to influenza viruses. The use of purified, adjuvanted antigen influenza vaccine (TIV) as the stimulus to 
measure cellular responses in vitro would possibly lead to greater T cell responses. Our results demonstrated 
that LAIV induced influenza-specific cytokine-producing CD8+ and CD4+ T cells, including TRM T cells in 
the lung. Such cells are important during influenza infection in protection of mucosal barrier tissues against 
pathogen challenge by producing chemokines for cell recruitment (53). It has been shown that TRM T cells 
provide superior protection against influenza infection when compared with circulating T cells (54). By seeding 
the lungs with these cells, it is possible to establish long-term heterosubtypic protection to influenza (55, 56).
We have also demonstrated that, in volunteers who were not colonized by S. pneumoniae, LAIV 
increased levels of  Tregs in the lung compared with unvaccinated individuals. CD4+ Tregs contribute to 
homeostasis of  the immune system, controlling infection by respiratory viruses and avoiding secondary 
bacterial infection (57). As a result of  recurrent exposure to virus and bacteria, CD4+ Tregs increase in 
frequency with age (58). For this reason, our findings in adults might underestimate the effect of  LAIV on 
frequency of  Tregs in the lungs of  children.
Although LAIV- and TIV-mediated responses were assessed in the context of  a randomized clinical 
trial, the study was limited by evaluation of  a single pneumococcal serotype in healthy adults likely to 
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have neutralizing influenza antibodies and cross-reactive T cells. In addition, we evaluated pneumococcal 
and live attenuated virus vaccine interaction during the early stages of  pneumococcal colonization, when 
host responses to bacterial exposure may be higher compared with later time points. It is possible that this 
short-term window may not reflect accurately the overall effect of  a colonization episode on LAIV immune 
responses. Any LAIV effect in children may be different owing to lower antibody titers against influenza, 
higher natural rates of  pneumococcal colonization, and higher levels of  inflammation compared with young 
adults (59). A future pediatric study, whereby colonization status is assessed before LAIV administration 
and correlated with immune responses to the vaccine, would provide important insights into the magnitude 
of  pneumococcal effect on vaccine immunogenicity in this population.
In conclusion, using a controlled human model in which pneumococcal infection occurred at a 
known time relative to vaccination, we were able to highlight differences in immunogenicity between 
LAIV and TIV at relevant mucosal sites. Moreover, we identified S. pneumoniae colonization as an 
important variable in LAIV-induced immunity.
Methods
Study design. Adult volunteers were enrolled in the parent LAIV clinical trial study (REC 14/NW/1460; 
ref. 26). Exclusion criteria included a prior history of  influenza or pneumococcal vaccination, clinically 
confirmed pneumococcal disease in the preceding 2 years, pregnancy, close contact with individuals at 
increased risk for pneumococcal disease (children under 5, immunosuppressed people, and elderly peo-
ple), recent febrile illness, current or recent use of  antibiotics, or immune-modulating medication. Partici-
pants were inoculated with 80,000 CFU per nostril of  serotype 6B as previously described (25). All volun-
teers received an influenza vaccination 3 days after pneumococcal inoculation. The LAIV group (n = 80) 
received the LAIV (2016/2017 Fluenz Tetra), whereas the TIV group (n = 90) received the TIV (2016/2017 
Fluarix Tetra). These 2 vaccine formulations had the same combination of  influenza A and influenza B 
strains. The overall carriage rates did not differ between the LAIV and TIV groups as measured by conven-
tional microbiology (37/80 [46.3%] vs. 45/90 [50.0%], respectively).
For investigation of  immune responses, samples of  nasal wash, nasal lining fluid, nasal cells, BAL, 
and serum were collected from volunteers at specific time points, processed, and frozen for future analysis 
(Supplemental Figure 1). For comparisons within the lung data sets, BAL fluid and lung lymphocytes from 
an unvaccinated EHPC group (n = 20, 10 S. pneumoniae– and 10 S. pneumoniae+) were used as a control.
Detection of  S pneumoniae colonization. To detect bacteria in the nasopharynx, nasal wash sample 
plates were examined by classical microbiology for presence of  S. pneumoniae as previously described 
(60, 61). Colonized individuals were defined as anyone who had a positive nasal wash sample at any time 
point following inoculation.
BAL analysis. A BAL sample was collected at the end of  the trial, between 26 and 46 days after vacci-
nation. Bronchoscopy was performed using topical anesthesia, and BAL was collected as described previ-
ously (62). Briefly, a total of  200 mL warm 0.9% saline was instilled and retrieved from a subsegmental 
bronchus of  the right middle lobe by hand suction. BAL was placed into sterile tubes on ice and processed 
as previously described (62). Next, the BAL sample was filtered to remove mucus and centrifuged at 400g 
for 10 minutes. BAL cells were resuspended in RPMI medium with antibiotic mixture (Penicillin-Strep-
tomycin-Neomycin, Thermo Fisher Scientific). Cells were plated in a 24-well plate (Greiner Bio-One) to 
allow macrophages to adhere for 4 hours at 37°C, 5% CO2. Nonadherent BAL cells were collected, washed, 
centrifuged at 200g for 10 minutes, and resuspended in RPMI medium prior to stimulation.
Intracellular cytokine staining. Nonadherent BAL cells were counted and incubated at 1 × 106 cells/mL in 
medium with RPMI medium FBS (10% heat inactivated, Thermo Fisher Scientific) and antibiotic mixture 
(Penicillin-Streptomycin-Neomycin) at 37°C. Samples were stimulated with 1.2 μg/mL influenza antigens 
(TIV, 2016/2017) or left unstimulated as negative control and incubated for 2 hours. Then, 1000× diluted 
GolgiPlug (BD Biosciences) was added, and cells were cultured for an additional 16 hours.
After 16 hours, the cells were washed with 3 mL PBS, resuspended, and stained with Violet Viability dye 
(LIVE/DEAD Fixable Dead Cell stain kit, Thermo Fisher Scientific). After 15 minutes, the cells were stained 
with the surface markers CD3-APC-H7 (clone SK7) and TCR-γδ–PECy7 (clone 11F2) from BD Biosciences 
and CD4–PerCP5.5 (clone SK3), CD8–AF700 (clone SK1), CD69–BV650 (clone FN5O), CD25-PE.TxsRed 
(clone M-A251), CD103–BV605 (clone Ber-ACT8), and CD49a-APC (clone TS2/7) (all from BioLegend) 
and incubated for 15 minutes. Cells were fixed and permeabilized using the Foxp3/Transcription Factor 
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Staining Buffer Set (eBioscience, Thermo Fisher Scientific) as per the manufacturer’s instructions. Cells were 
then stained with intracellular markers FOXP3-FITC (clone 259D), IFN-γ–PE (clone 4S.B3), and TNF-α–
BV711 (clone MAb11) (all from BioLegend) and IL-10–BV786 (clone JES3-9D7) IL-17A–BV510 (clone N49-
653) from BD Biosciences. After 30 minutes, samples were washed with 3 mL PBS and resuspended in 200 
μL PBS and acquired on a BD LSR flow cytometer (Becton Dickinson). Flow cytometry data were analyzed 
using cell analysis software version 10 (FlowJo, LLC).
Quantitative reverse-transcription PCR. Quantitative reverse-transcription PCR was used to quantify nasal virus 
shedding in volunteers vaccinated with LAIV. RNA was isolated (RNeasy kit; Qiagen) from nasal wash fluid, 
following generation of cDNA (high-capacity RT kit; Applied Biosystems, Thermo Fisher Scientific) for use 
in quantitative PCR (SYBR Green PCR master mix; Applied Biosystems, Thermo Fisher Scientific). Samples 
were tested using primers, probes, and PCR assay conditions specific for human influenza virus A and B (63). 
Results were analyzed using the cycle threshold (2 ΔΔCt) method by comparison with GAPDH transcription.
ELISA. ELISA was used to quantify levels of  IgG and IgA antibodies against influenza in the serum, 
as well as IgG, IgA, and IgM in nasal wash and BAL supernatant of  volunteers vaccinated with TIV or 
LAIV or unvaccinated. Pooled serum of  7 TIV vaccinated volunteers was heat-inactivated (at 56°C for 30 
minutes) and used as standard in both total IgA and IgG against influenza ELISA. Antibody levels were 
expressed in arbitrary units relative to this standard curve. For IgG detection, an initial standard dilution of  
1:4000 was used, whereas for IgA it was diluted 1:40.
Briefly, 96-well plates (Nunc) were coated with 100 μL 0.2 μg/mL TIV in PBS overnight at room tem-
perature. After the overnight incubation, plates were washed following blocking with 100 μL PBS with 1% 
BSA for 1 hour at room temperature. Plates were washed, and then samples were added in duplicates and 
incubated for 2 more hours at room temperature. Each wash consisted of  washing the plate 3 times with 
PBS with 0.005% Tween 20 (MilliporeSigma).
For detection of  IgG, IgA, and IgM, a 1:5000, 1:4000, and 1:2000 dilution of  anti-human IgG (Mil-
liporeSigma, A9544), anti-human IgA (MilliporeSigma, A9669), and anti-human IgM (MilliporeSigma, 
A3437), respectively, was made using 0.1% BSA and 100 μL added to each well after washing and incubat-
ed at room temperature for 1 hour.
Next, plates were washed, and 100 μL p-Nitrophenyl Phosphate (MilliporeSigma) was added to the 
wells. The OD of  each well was measured at 405 nm using a FLUOstar Omega ELISA microplate reader 
(BMG Labtech), the average blank corrected value was calculated for each sample, and the data analyzed 
using Omega Analysis (BMG Labtech).
Luminex analysis of  nasal lining fluid. Nasal lining fluid was collected using nasosorption filters as pre-
viously described (64) and stored at –80°C until analysis. Prior to analysis, cytokines were eluted from 
stored filters using 100 μL assay diluent buffer (Thermo Fisher Scientific) by centrifugation. The eluate 
was cleared by further centrifugation at 16,000g for 10 minutes. Samples were acquired on an LX200 
using a 30-plex magnetic human Luminex cytokine kit (Thermo Fisher Scientific), and results were ana-
lyzed with xPonent3.1 software (Luminex) following the manufacturer’s instructions. Samples were ana-
lyzed in duplicates, and cytokines with a coefficient of  variation of  more than 25% for a given sample 
were excluded from further analysis.
RNA extraction and sequencing. Nasal cells were collected in RNALater (Thermo Fisher Scientific) at –80°C 
until extraction. RNA extraction was performed using the RNEasy Micro Kit (Qiagen) with on-column DNA 
digestion. Extracted RNA was quantified using a Qubit (Thermo Fisher Scientific). Sample integrity assess-
ment (Bioanalyzer, Agilent), library preparation, and RNA-Seq (Illumina Hiseq4000, 20 million reads, 100 
paired-end reads) were performed at the Beijing Genome Institute.
RNA-Seq analysis. Quality control of raw sequencing data was done using fastQC. Mapping to a human 
reference genome assembly (GRCh38) was done using STAR 2.5.0a (65). Read counts from the resulting BAM 
alignment files were obtained with featureCounts using a GTF gene annotation from the Ensembl database 
(66, 67). The R/Bioconductor package DESeq2 was used to identify differentially expressed genes among the 
samples, after removing absent features (0 counts) (68). Genes with an FDR value of less than 0.1 and an abso-
lute FC of more than 1.5 (baseline-normalized values) were identified as differentially expressed. For each time 
point comparison, gene set enrichment analysis was performed using the fgsea R package. Genes with Ensembl 
IDs were transformed into gene symbols by the biomaRt package (69) and ordered by their log FC values. 
Preranked genes and Reactome gene sets from Enrichr (70) were provided to fgsea, with remaining default 
parameters. To identify significant common pathways between all comparisons, pathways with a P value below 
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a threshold of 0.05 for at least 1 comparison were selected and clustered based on the NES with hierarchical 
clustering. Correlation plots were generated to display the NES values using the corrplot package.
Data availability. Raw RNA-Seq data have been deposited in the National Center for Biotechnology 
Information’s Gene Expression Omnibus repository, accession number GSE164649. All other underlying 
data are provided in the manuscript.
Statistics. All sampling, processing, and data analysis were performed while blinded to vaccination 
group to not bias results. Nonparametric tests were used for statistical analysis where number of  samples 
was insufficient for a normal distribution of  results. Statistics were calculated in GraphPad Prism software, 
version 6.0 and 7.0 for Windows, and R statistical software (R Foundation for Statistical Computing). A P 
value of  less than or equal to 0.05 was considered significant. Benjamini-Hochberg multiple correction was 
performed in R on both 30-plex cytokine data and RNA-Seq data analysis.
Study approval. Ethical approval was given by the North West-Liverpool East Research Ethics Commit-
tee (REC) reference number 14/NW/1460. The trial was registered on EudraCT, Protocol 2014-004634-26 
(NCT ID: NCT03502291). All volunteers gave written informed consent, and research was conducted in 
compliance with all relevant ethical regulations. BAL samples of  the control (nonvaccinated cohort) were 
collected at part of  a separate EHPC clinical trial (REC 15/NW/0931).
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